Summit Therapeutics (SMMT) stock slips as Bernstein downgrades the company to Underperform from Market Perform, citing concern over its R&D efforts. Read more here.
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
Summit Therapeutics has seen its modeled fair value per share edge down from US$30.07 to US$29.41, which gives you an updated reference point for where some analysts see long term worth. This subtle shift lines up with recent research that weighs the US$2b AstraZeneca partnership and lung cancer program optimism against questions on valuation, trial outcomes, and competitive pressures. As you read on, you will see how these moving targets shape the evolving analyst story around Summit...
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Summit Therapeutics remains a 'Hold': U.S. translation risk and approaching HARMONi-3 data make ivonescimab a binary bet. Click to read more on SMMT stock.
Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug.
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
Summit falls on cancer drug approval setback, Nvidia headlines the week’s earnings, and more…
The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.
The FDA said Summit's ivonescimab didn't show a significant survival benefit.
Summit Therapeutics says FDA declines ivonescimab plus chemotherapy approval for advanced lung cancer, citing insufficient evidence of longer survival.
MIAMI, October 21, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab pl
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
This is the newest page. Registered accounts read further back.